National IAS–USA Virtual Update Course on HIV Management

National IAS–USA Virtual Update Course on HIV Management

Registration Details

  • Preregistration: $35.00 (USD)
  • Preregistration ends: Thursday, November 12, 2020


Roger J. Bedimo, MD, MS
University of Texas Southwestern Medical Center
Connie L. Celum, MD, MPH
University of Washington
Judith S. Currier, MD
University of California Los Angeles
Jodie A. Dionne-Odom, MD, MSPH
University of Alabama at Birmingham
Ann R. Falsey, MD
University of Rochester School of Medicine
Monica Gandhi, MD, MPH
University of California San Francisco
Henry Masur, MD
George Washington University School of Medicine
Gregorio Millett, MPH
amfAR, The Foundation for AIDS Research
E. Turner Overton, MD
University of Alabama at Birmingham
Michael S. Saag, MD
University of Alabama at Birmingham
Susan Swindells, MBBS
University of Nebraska Medical Center

November 12, 2020

12:00 PM - 4:35 PM ET

If you registered for the course before 8:00AM PT on Wednesday, November 11, an email from Zoom (be sure to add to your “safe sender” list) with your personal link to access the virtual course was sent to you today, November 11 at 1:00 PM ET. You will also receive a 1-hour reminder on Thursday, November 12 at 11:00 AM ET (8:00 AM PT, 9:00 AM MT, 10:00 AM CT). Please check your spam folder if you did not receive an email.

If you registered after 8:00 AM PT on Wednesday, instructions on how to join are included in your registration confirmation message. Please be sure to click on the link provided in the email to get your personal link to access the virtual course. Registration is still open till the course end.

Presentation Topics

  • What You May Have Missed at IDWeek 2020: Implications for HIV Care and Treatment
  • PEP and PrEP in the Era of COVID-19: A Case-Based Discussion
  • Projected HIV Policy Changes in 2021
  • Update on the Clinical Management of HIV: A Case-Based Discussion
  • Where We Stand Today on a SARS-CoV-2 Vaccine


Program Description

Because we know it is difficult for you to dedicate an entire day to participating in a virtual course at present, this national virtual update will concentrate on the key issues on which most of you are likely focusing. We will cover other topics related to comorbidities, issues in aging, and so on in our COW webinar programming, which you can access live or on demand.

This course is scheduled to accommodate HIV clinicians in most US time zones and is open to all.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs and approaches
  • Identify situations in which the choice of antiretroviral regimens should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Initiate and monitor HIV prevention intervention strategies, including the use of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the status of vaccine development for COVID-19
  • Describe the possible changes to HIV public policy in 2021

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 4 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for 4 hours of pharmacotherapy credit.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 4 contact hours (0.4 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-20-348-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare


Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.